367 related articles for article (PubMed ID: 31764118)
21. Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia.
Mauro FR; Caputo MD; Rosati S; Pepe S; De Benedittis D; De Luca ML; Foà R
Expert Rev Hematol; 2018 Aug; 11(8):601-611. PubMed ID: 29969322
[TBL] [Abstract][Full Text] [Related]
22. The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.
Jacobs RW; Awan FT; Leslie LA; Usmani SZ; Ghosh N
Expert Rev Hematol; 2016 Dec; 9(12):1177-1187. PubMed ID: 27791448
[TBL] [Abstract][Full Text] [Related]
23. Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia.
Gimenez N; Tripathi R; Giró A; Rosich L; López-Guerra M; López-Oreja I; Playa-Albinyana H; Arenas F; Mas JM; Pérez-Galán P; Delgado J; Campo E; Farrés J; Colomer D
Sci Rep; 2020 Dec; 10(1):22153. PubMed ID: 33335123
[TBL] [Abstract][Full Text] [Related]
24. Current Perspectives on Therapy for Chronic Lymphocytic Leukemia.
Awan FT; Al-Sawaf O; Fischer K; Woyach JA
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-10. PubMed ID: 32239979
[TBL] [Abstract][Full Text] [Related]
25. Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL.
Mhibik M; Wiestner A; Sun C
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861854
[TBL] [Abstract][Full Text] [Related]
26. Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T.
Wiedmeier-Nutor J; Leis J
Curr Treat Options Oncol; 2022 Jun; 23(6):904-919. PubMed ID: 35435617
[TBL] [Abstract][Full Text] [Related]
27. BTK Inhibitors and Chemoimmunotherapy for CLL.
Thompson P
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S22-S24. PubMed ID: 32862855
[No Abstract] [Full Text] [Related]
28. Targeting B Cell Signaling in Chronic Lymphocytic Leukemia.
Arnason JE; Brown JR
Curr Oncol Rep; 2017 Sep; 19(9):61. PubMed ID: 28755313
[TBL] [Abstract][Full Text] [Related]
29. First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?
Cherng HJ; Jain N
Hematol Oncol Clin North Am; 2021 Aug; 35(4):725-738. PubMed ID: 34174983
[TBL] [Abstract][Full Text] [Related]
30. Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.
Molica S; Giannarelli D; Baumann T; Montserrat E
Eur J Haematol; 2020 May; 104(5):512-515. PubMed ID: 31957067
[No Abstract] [Full Text] [Related]
31. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections.
Hilal T; Gea-Banacloche JC; Leis JF
Blood Rev; 2018 Sep; 32(5):387-399. PubMed ID: 29571669
[TBL] [Abstract][Full Text] [Related]
32. Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.
Feng G; Wang X
Leuk Lymphoma; 2014 Dec; 55(12):2699-705. PubMed ID: 24547708
[TBL] [Abstract][Full Text] [Related]
33. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
[TBL] [Abstract][Full Text] [Related]
34. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
35. Ascorbic acid (vitamin C) synergistically enhances the therapeutic effect of targeted therapy in chronic lymphocytic leukemia.
Darwiche W; Gomila C; Ouled-Haddou H; Naudot M; Doualle C; Morel P; Nguyen-Khac F; Garçon L; Marolleau JP; Ghamlouch H
J Exp Clin Cancer Res; 2020 Oct; 39(1):228. PubMed ID: 33115525
[TBL] [Abstract][Full Text] [Related]
36. B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.
Hill RJ; Lou Y; Tan SL
Int Rev Immunol; 2013 Aug; 32(4):377-96. PubMed ID: 23886341
[TBL] [Abstract][Full Text] [Related]
37.
Rassenti LZ; Balatti V; Ghia EM; Palamarchuk A; Tomasello L; Fadda P; Pekarsky Y; Widhopf GF; Kipps TJ; Croce CM
Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10731-10736. PubMed ID: 28923920
[TBL] [Abstract][Full Text] [Related]
38. [Research Progress of Targeted Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma --Review].
Chen D; Wang MY; Tian C
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):643-646. PubMed ID: 38660880
[TBL] [Abstract][Full Text] [Related]
39. Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia.
Rossi D; Gerber B; Stüssi G
Leuk Lymphoma; 2017 Jul; 58(7):1548-1560. PubMed ID: 27808579
[TBL] [Abstract][Full Text] [Related]
40. BCL-2 as a therapeutic target in chronic lymphocytic leukemia.
Daniel C; Mato AR
Clin Adv Hematol Oncol; 2017 Mar; 15(3):210-218. PubMed ID: 28398276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
